Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2)

Pediatric Blood and Cancer

Volumn 53, Issue 1, 2009, Pages 53-57

  Zehnder, Aina ^a   Fisch, Urs ^a   Hirt, Andreas ^a   Niggli, Felix K ^b   Simon, Arne ^c   Ozsahin, Hulya ^d   Schlapbach, Luregn J ^a   Ammann, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cancer; Innate immunity; Mannose binding lectin (MBL); MBL associated serine protease 2 (MASP 2); Prognosis; Risk group assignment

Indexed keywords

MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG; MASP2 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; BLOOD; BLOOD DISEASE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; METABOLISM; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SURVIVAL RATE;

CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 66149125261     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22028     Document Type: Article

References (22)

1. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-2715.
2. Lehrnbecher T, Koehl U, Wittekindt B, et al. Changes in host defence induced by malignancies and antineoplastic treatment: Implication for immunotherapeutic strategies. Lancet Oncol 2008;9:269-278.
3. de Visser KE, Coussens LM. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 2005;54:1143-1152. (Pubitemid 41396818)
4. Sørensen R, Thiel S, Jensenius JC. Mannan-binding-lectin- associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol 2005;27:299-319. (Pubitemid 41639883)
5. Staros EB. Innate immunity: New approaches to understanding its clinical significance. Am J Clin Pathol 2005;123:305-312. (Pubitemid 40194095)
6. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol 2007;44:3875-3888. (Pubitemid 47337117)
7. Crosdale DJ, Ollier WE, Thomson W, et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK caucasoids. Eur J Immunogenet 2000;56:630-641.
8. Roos A, Garred P, Wildenberg ME, et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol 2004;34:2589-2598. (Pubitemid 39302816)
9. Schlapbach LJ, Aebi C, Otth M, et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenic pediatric cancer patients. Pediatr Blood Cancer 2007;49:11-16. (Pubitemid 46847063)
10. Schlapbach LJ, Aebi C, Otth M, et al. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2007;26:989-994. (Pubitemid 350287579)
11. Pine SR, Mechanic LE, Ambs S, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007;99:1401-1409. (Pubitemid 351767188)
12. Ytting H, Christensen IJ, Thiel S, et al. Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: Relation to recurrence and mortality. Clin Cancer Res 2005;11:1441-1446. (Pubitemid 40315224)
13. Ytting H, Christensen IJ, Thiel S, et al. Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 - A prognostic marker in colorectal cancer. Hum Immunol 2008;69:414-420.
14. Frakking FNJ, Brouwer N, Dolman KM, et al. Mannose-binding lectin (MBL) as prognostic factor in pediatric oncology patients. In: Frakking FNJ, editor. The clinical significance of mannose-binding lectin (MBL) deficiency. [MD dissertation] Amsterdam: Academic Medical Center. University of Amsterdam; The Netherlands: 2008. pp 97-112.
15. Schmiegelow K, Garred P, Lausen B, et al. Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood 2002;100:3757-3760. (Pubitemid 35303948)
16. Steliarova-Foucher E, Stiller CA, Lacour B, et al. International classification of childhood cancer, third edition. Cancer 2005;103:1457-1467. (Pubitemid 40410743)
17. Altman DG. Practical statistics for medical research. Chapman & Hall London: 1991. 611 p.
18. Minchinton RM, Dean MM, Clark TR, et al. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002;56:630-641. (Pubitemid 35454347)
19. Yefenof E, editor. Innate and adaptive immunity in the tumor microenvironment. Springer New York: 2008. 212 p.
20. Hobohm U. Fever therapy revisited. Br J Cancer 2005;92:421-425. (Pubitemid 40395520)
21. Fisher RI, DeVita VT, Jr., Bostick F, et al. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med 1980;92:595-599. (Pubitemid 10107546)
22. Slivnick DJ, Ellis TM, Nawrocki JF, et al. The impact of Hodgkin's disease on the immune system. Semin Oncol 1990;17:673-682.